Option Care Health (OPCH)
(Delayed Data from NSDQ)
$29.58 USD
+0.82 (2.85%)
Updated Oct 11, 2024 04:00 PM ET
Pre-Market: $29.90 +0.32 (1.08%) 9:14 AM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.58 USD
+0.82 (2.85%)
Updated Oct 11, 2024 04:00 PM ET
Pre-Market: $29.90 +0.32 (1.08%) 9:14 AM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Top Ranked Momentum Stocks to Buy for September 14th
by Zacks Equity Research
RRC, OPCH, CNQ, and ARES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 14, 2021.
What Makes Option Care (OPCH) a Good Fit for "Trend Investing"
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Option Care (OPCH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
3 MedTech Sectors Benefiting Despite COVID-19 Resurgence
by Urmimala Biswas
Here we discuss three major subsectors of MedTech and some of their constituent stocks for which COVID-19 has opened up enormous growth prospects.
Can Option Care (OPCH) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Option Care (OPCH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Recent Price Trend in Option Care (OPCH) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Option Care (OPCH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
New Strong Buy Stocks for August 16th
by Zacks Equity Research
CVLG, DDS, MHO, OPCH, and TUP have been added to the Zacks Rank #1 (Strong Buy) List on August 16, 2021.
Option Care (OPCH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 125.00% and 9.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Option Care (OPCH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Option Care (OPCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Option Care (OPCH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of -200.00% and 0.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Option Care Health (OPCH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (OPCH) Outperforming Other Medical Stocks This Year?
Option Care (OPCH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 42.86% and 0.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Option Care (OPCH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Option Care (OPCH) closed at $19.54 in the latest trading session, marking a -1.19% move from the prior day.
What's in Store for Fulgent Genetics (FLGT) in Q4 Earnings?
by Zacks Equity Research
We expect strong demand for Fulgent Genetics' (FLGT) end-to-end tests for COVID-19 to have continued through the fourth quarter.
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect weak segmental performance.
Option Care (OPCH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Option Care (OPCH) closed at $18.97, marking a +0.58% move from the previous day.
Is Option Care Health (OPCH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (OPCH) Outperforming Other Medical Stocks This Year?
Owens & Minor (OMI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
We expect the strength in demand for Owens & Minor's (OMI) PPEs to have continued through the fourth quarter.
Option Care (OPCH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Option Care (OPCH) closed the most recent trading day at $19.86, moving +0.2% from the previous trading session.
Lower Bulk Purchases May Weigh on Medtronic (MDT) Q3 Earnings
by Zacks Equity Research
Medtronic's (MDT) diabetes care, robotics surgery and neuromodulation lines are expected to have performed well in Q3.
Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to reflect gains from the Global Healthcare and Life Sciences segment.
OPKO Health (OPK) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.
Invitae (NVTA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Invitae's (NVTA) fourth-quarter results are likely to reflect strength in genetic testing.
Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?
by Zacks Equity Research
Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).
Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q4.
Exact Sciences (EXAS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.